HOME >> MEDICINE >> NEWS
Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression

ROCHESTER, Minn. -- A new immunosuppression regimen for heart transplant patients can improve kidney function and prevent transplant coronary artery disease, according to two new Mayo Clinic studies. Mayo researchers will report their findings on April 26 at The International Society for Heart & Lung Transplantation Annual Meeting and Scientific Session in San Francisco.

Heart transplant patients are required to take daily immunosuppressive medication to prevent their body from rejecting the transplanted organ. Standard practice has been to treat patients primarily with calcineurin inhibitors. However, calcineurin inhibitors are a major cause of kidney dysfunction and do not prevent transplant coronary artery disease, a rapidly progressing coronary disease that develops in many heart transplant recipients and greatly limits long-term survival.

"Immunosuppression for heart transplant patients using calcineurin inhibitors has been essentially unchanged for 25 years, and the results have not been ideal," says Sudhir Kushwaha, M.D., the lead author and a cardiologist at Mayo Clinic. "Five to 10 years post-transplant, 10 percent of patients are on dialysis or need a kidney transplant. And 10 years post-transplant, 50 percent of patients are either waiting for another heart transplant because of coronary artery disease or have died as a result of it."

Dr. Kushwaha and a team of Mayo Clinic researchers collaborated to study alternative options for immunosuppression, using sirolimus, an anti-proliferative immunosuppression drug with potent anti-rejection properties.

One study involving 78 heart transplant patients over four years found that gradually transitioning stable patients from calcineurin inhibitors to sirolimus showed consistent improvement of kidney function. There was no increase in rejection of the transplanted heart and no difference in heart function.

A second study found gradual transition to sirolimus
'"/>

Contact: Elizabeth Rice
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
26-Apr-2007


Page: 1 2

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. New Mayo Clinic MRI technology enables noninvasive liver diagnoses
6. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
7. Elsevier launches the Clinics on ScienceDirect
8. Clinical guidelines for blood conservation during cardiac procedures developed
9. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
10. Mayo Clinic research in cardiovascular disease presented at Experimental Biology 2007
11. Clinical trial coordinators need more financial conflict-of-interest training

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2019)... ... November 15, 2019 , ... ... webinar on comprehensive school physical activity programs (CSPAP) on December 3, 2019 at ... recreation and park professionals, this one-hour and 15-minute webinar will discuss the five ...
(Date:11/14/2019)... ... , ... With Giving Tuesday on Dec. 3, 2019, the ... about the benefits of supporting local hospitalized veterans throughout Maryland. Created in 2012, ... to give, collaborate and celebrate generosity before the holidays, and enables participants to ...
(Date:11/14/2019)... ... November 14, 2019 , ... BioInformatics Inc., part of Science and ... today announced that 7 companies have been nominated for a Life Science Industry ... Since 2002, the Life Science Industry Awards have recognized manufacturers of the “tools of ...
(Date:11/12/2019)... Ind. (PRWEB) , ... November 12, 2019 , ... ... a select group of individuals/organizations who have truly impacted those diagnosed with infertility. ... received RESOLVE’s prestigious Hope Award for Achievement, presented at the Night of Hope ...
(Date:11/12/2019)... ... 2019 , ... The quality of study start-up can dictate ... contract negotiations and 80 percent of organizations still using spreadsheets to track activities, ... improvement. Following an overview of the challenges facing trial sponsors, this webinar will ...
Breaking Medicine News(10 mins):
(Date:11/11/2019)... ... November 11, 2019 , ... PRP Science , Florida’s ... is now representing two of the most respected manufacturers in the medical aesthetics arena; ... Ameia Med is the leading developer of the EXCEED micro-needling device ...
(Date:11/11/2019)... ... November 11, 2019 , ... Attorneys representing an ... statement before U.S. Bankruptcy Court Judge Robert Drain in White Plains, NY notifying ... prescription opioid epidemic cannot be forgotten as a $12 billion settlement is considered. ...
(Date:11/11/2019)... ... November 11, 2019 , ... Over 60 schools in the northwest panhandle of ... program is designed to provide virtual mental health care to more than 35,000 students ... in October of 2018 [1]. , “This initiative by the state of Florida,” says ...
Breaking Medicine Technology:
Cached News: